BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

VGX Pharmaceuticals (Formerly Known as Viral Genomix, Inc.) Announces Agreement With the PATH Malaria Vaccine Initiative


3/23/2009 10:00:24 AM

BLUE BELL, Pa.--(BUSINESS WIRE)--VGX Pharmaceuticals (VGX), a developer of DNA vaccines and therapies against cancer and infectious diseases, announced today an agreement with the PATH Malaria Vaccine Initiative (MVI) to evaluate in a preclinical feasibility study VGX’s SynCon™ DNA vaccine development platform. More specifically, VGX will design and test DNA vaccine candidates using target antigens from Plasmodium species and deliver them intradermally using the CELLECTRA® constant current electroporation device. The collaboration brings together vaccine development and malaria experts from the University of Pennsylvania School of Medicine and VGX.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->